(Q27003961)

1

1 reference

L. Sawyer

2

1 reference

R. Tucker

4

1 reference

C.H. Smith

5

1 reference

language of work or name

1 reference

May 2013

1 reference

British Journal of Dermatology

published in

1 reference

volume

168

1 reference

issue

5

1 reference

page(s)

954-67

1 reference

Psoriasis causes as much disability as other major medical diseases

cites work

1 reference

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

21 January 2018

1 reference

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

21 January 2018

1 reference

Psoriasis and its management

21 January 2018

1 reference

Maximizing patient adherence for optimal outcomes in psoriasis

21 January 2018

1 reference

Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis.

21 January 2018

1 reference

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

21 January 2018

1 reference

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis

21 January 2018

1 reference

A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris

21 January 2018

1 reference

Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks

21 January 2018

1 reference

Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study

21 January 2018

1 reference

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

21 January 2018

1 reference

Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical tria

21 January 2018

1 reference

Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis

21 January 2018

1 reference

Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial

21 January 2018

1 reference

Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy

21 January 2018

1 reference

A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris

21 January 2018

1 reference

A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis.

21 January 2018

1 reference

A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis

21 January 2018

1 reference

Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris

21 January 2018

1 reference

A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis

21 January 2018

1 reference

Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study

21 January 2018

1 reference

Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy

21 January 2018

1 reference

A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial

21 January 2018

1 reference

Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.

21 January 2018

1 reference

Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis

21 January 2018

1 reference

A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial

21 January 2018

1 reference

A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial

21 January 2018

1 reference

Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis.

21 January 2018

1 reference

A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis

21 January 2018

1 reference

Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland - results of a survey of Scottish health professionals

21 January 2018

1 reference

Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial

21 January 2018

1 reference

release_n57npetv7vhb3ido6pvzyjrqsq

21 January 2018

Identifiers

DOI

10.1111/BJD.12276

0 references

Fatcat ID

0 references

PubMed publication ID

23413913

1 reference